A 60 year-old man with a history of prostate cancer who underwent radical prostatectomy is currently being treated with androgen-deprivation therapy and is on a clinical trial with bevacizumab (Avastin, an antiangiogenic and anti-vascular endothelia growth factor [VEGF] chemotherapy) for an elevated prostate-specific antigen. At clinic visits after starting bevacizumab, he was noted to have new hypertension, with blood pressure as high as 178/98 mm Hg. After his second cycle of bevacizumab, he had sudden onset of palpitations, with workup revealing atrial fibrillation. He spontaneously cardioverted back to sinus rhythm but was referred to our institution's cardiology clinic for oncology patients (Cardio-Oncology Clinic) for management of hypertension and atrial fibrillation in the setting of bevacizumab therapy.
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Angiogenesis, the formation of new blood vessels from preexisting ones, is required for the growth and metastases of solid tumors. 1 Angiogenesis is mediated by the stabilization of the master transcription factor (hypoxia-inducible factor-␣), leading to transcription of a number of protumorigenic factors, including VEGF. Inhibiting this pathway has served as a target for antineoplastic treatment, and over the last 5 years, VEGF signaling pathway (VSP) inhibitors have been approved for the treatment of a broad spectrum of malignancies (the Figure) . With increased clinical use, these agents have been shown to have cardiovascular side effects, most commonly hypertension, but also arterial or venous thrombotic events and heart failure. This review outlines the presentation, pathophysiology, and our approach to the diagnosis and treatment of VSP inhibitor-induced hypertension, and briefly highlights other cardiac complications that may occur in patients receiving these agents.
Pharmacology of Angiogenesis Inhibitors
The VEGF family of growth factors includes 4 distinct proteins, VEGF A through VEGF D, with VEGF-A (referred to here as VEGF) being the most clinically relevant, promoting angiogenesis in tumor cells through several distinct effects. 1 The 3 VEGF receptors, VEGFR-1, -2, and -3, are members of the receptor tyrosine kinase family. Of these, VEGFR-2 is most robustly expressed on endothelial cell membranes and mediates the above angiogenic effects. 1 Decreasing VEGF activity by targeting the growth factor itself or its receptor is a primary strategy underlying a new wave of targeted oncological therapies (the Figure) .
The first clinically available VSP inhibitor, bevacizumab, a monoclonal antibody targeted against soluble VEGF protein, was approved by the Food and Drug Administration in 2004 for the treatment of metastatic colon cancer. 2 Since then, small receptor tyrosine kinase inhibitors, with potent VEGFR-2 inhibition, have been approved for an array of malignancies (Table 1) , with many more in various stages of development ( Table 2 ). Receptor tyrosine kinase inhibitors are not entirely specific for VEGFR-2, and target other tyrosine kinase receptors. For example, sunitinib and sorafenib, the first receptor tyrosine kinase inhibitors with potent anti-VEGFR inhibition, also target platelet-derived growth factor receptor, as well as c-kit (receptor for stem cell factor). The multiple receptor tyrosine kinase targets of these drugs have implications both for their therapeutic potency and for their cardiotoxicities.
Hypertension
Initial clinical trials with bevacizumab first identified hypertension in 28% of the patients 3 ; subsequent trials with sorafenib, sunitinib, and pazopanib identified hypertension with similar frequency in all VSP inhibitors. Metaanalyses have shown the incidence of hypertension to be Ϸ19% to 24% in all VSP inhibitors. 4, 5 However, these data may underestimate the true incidence of hypertension in clinical practice today.
Only recently has the classification system used by the National Cancer Institute to assess toxicities associated with novel chemotherapies been up-dated to more closely reflect the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) guidelines for 
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Schematic of vascular endothelial growth factor (VEGF) pathway and sites of action of VEGF signaling pathway inhibitors (modified from templates provided by www.proteinlounge.com). VEGFR indicates VEGF receptor; HIF, hypoxia-inducible factor; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; and TKI, tyrosine kinase inhibitor. hypertension (Table 3 ). Furthermore, patients in the general population may have more comorbidities, such as diabetes mellitus or preexisting hypertension, compared with highly selected trial patients. Therefore, nontrial patients may be at increased risk of developing VSP inhibitor-induced hypertension. Finally, some newer VSP inhibitors currently in clinical trials (such as axitinib) are highly potent, and may have a higher incidence of hypertension. 4 In this regard, the incidence of hypertension is dependent on drug variables (type of drug, dose, and schedule used) and patients (age and previous history of hypertension or other cardiovascular disease). Nevertheless, an absolute blood pressure increase occurs in the majority of patients, with rapid onset after the first administration of the drug. Maitland and colleagues, 6 for example, report a mean blood pressure increase of 8.2 mm Hg systolic and 6.5 mm Hg diastolic in the first 24 hours after the first treatment with sorafenib, although the authors also noted substantial variation in blood pressure increase, with some patients having no increase in blood pressure and others experiencing a doubling in systolic blood pressure. We have reported a similar rapid rise in blood pressure in most patients starting treatment with cediranib, another highpotency VSP inhibitor. 7 Interestingly, the rise in blood pressure associated with VEGF inhibitors appears to reverse as rapidly as its onset, with a return of blood pressure to nearly baseline levels by the end of the off-treatment phase, 8 an observation that has implications for patient management.
Table 2. Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Under Investigation

Pathophysiology
A number of mechanisms have been proposed for VSP inhibitor-associated hypertension. Activation of VEGFR-2 by VEGF induces expression of nitric oxide (NO) synthase in endothelial cells, which promotes vascular permeability and vasodilation. 9 In fact, when VEGF agonists were used in an attempt to promote angiogenesis in models of ischemic cardiomyopathy, hypo-tension was one of the major side effects. 10 Treatment with VSP inhibitors both in vitro and in rodent models has been shown to decrease NO synthesis and to lead to hypertension. Moreover, a recent study in patients with metastatic renal cell carcinoma receiving VSP inhibitors shows suppression of the NO pathway. 11 These data suggest an important causal role for impaired NO production in the pathogenesis of VSP inhibitor-mediated hypertension.
Other mechanisms are likely playing roles. Loss of parallel capillary circulation in normal, nontumor tissue-a process called rarefactionhas also been associated with hypertension in patients being treated with VSP inhibitors. This pathology reverses with VSP inhibitor discontinuation. 12, 13 Other proposed mechanisms for VSP inhibitor-induced hypertension include endothelial dysfunction, leading to an increase in endothelin-1 and an increase in aortic stiffness.
There are intriguing similarities between the clinical features of VSPassociated hypertension and preeclampsia, a syndrome of hypertension and proteinuria affecting up to 5% of pregnant women. Preeclampsia has been associated with decreased VEGF signaling through increased circulating levels of a soluble VEGFR. 14 In this regard, proteinuria has been described across all VSP inhibitors. 15 Moreover, systemic endothelial dysfunction, a central feature in patients with preeclampsia, may play a pathological role in VSP-associated vascular thromboses (see below).
Management
There is a paucity of data to guide management of VSP inhibitor-associated hypertension. A recent assembly of the Cardiovascular Toxicities Panel of the National Cancer Institute set a goal of 140/90 mm Hg (and 130/ 80 mm Hg in patients with chronic kidney disease or diabetes mellitus) for Table 3 
. Comparison of National Cancer Institute and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Classifications of Hypertension
National Cancer Institute hypertension grading CTCAE, version 3.0, 2006 Grade 1: asymptomatic, transient (Ͻ24 h) increase by Ͼ20 mm Hg (diastolic) or to Ͼ150/100 if previously WNL; intervention not indicated Grade 2: recurrent or persistent (Ն24 h) or symptomatic increase by Ͼ20 mm Hg (diastolic) or to Ͼ150/100 mm Hg if previously WNL; monotherapy may be indicated all hypertensive patients on VSP inhibitors. 16 These recommendations are consistent with JNC7 guidelines, although the committee noted the lack of evidence-based data in this area. Despite the lack of data, several important points concerning treatment should be emphasized. Aggressive hypertension management before the initiation of VSP inhibitor therapy is critical. Blood pressure monitoring should be performed frequently, at least weekly for the first 6 weeks of treatment. We often suggest that high-risk patients (those with preexisting hypertension or other cardiac risk factors) use an automated home blood pressure cuff to measure blood pressure daily for the first 6 weeks. Lifestyle modification should be encouraged, including moderating alcohol intake and reducing dietary salt.
Because VSP inhibitors have been associated with the development of proteinuria, regular urinalysis should be performed as a screening test. If new proteinuria is detected, proteinuria should be quantified and selected patients should be referred to a nephrologist for further evaluation and treatment. We and others suggest angiotensin-converting enzyme inhibitors as a first-line therapy in these patients in the absence of any contraindications because these agents are effective at reducing blood pressure and proteinuria. 17 Sunitinib and sorafenib are metabolized by the CYP3A4 system, so nondihydropyridine calcium channel blockers (verapamil and diltiazem), which are CYP3A4 inhibitors, should be avoided in patients on these agents, but may be considered in patients on bevacizumab. Given the relationship between VEGF and NO, replacing the NO depletion induced by anti-VEGF agents with a long-acting nitrate or a phosphodiesterase inhibitor is an elegant, mechanistic treatment. Ultimately, VSP dose reduction or interruption may need to be considered in the case of severe, refractory hypertension or in the case of hypertensive crisis. Of note, after drug holiday, reinitiation of a different VSP inhibitor may be better tolerated.
In our practice, we recommend angiotensin-converting enzyme inhibitors or calcium channel blockers (specifically amlodipine or felodipine) as first-line agents in the treatment of VSP inhibitor-associated hypertension. We recommend rapid titration of antihypertensive therapy in the first week after VSP inhibitor initiation. We also recommend patient home blood pressure monitoring to facilitate titration remotely. If patients have systolic blood pressure Ͼ165 mm Hg or diastolic blood pressure Ͼ100 mm Hg, VSP inhibitor therapy should be held until antihypertensive therapy titration is consistent with NCI recommendations. 16 To avoid hypotension, we additionally recommend close blood pressure monitoring with a reduction of antihypertensive medications when VSP inhibitor therapy is stopped.
Other Cardiovascular Toxicities
Original clinical trials of VSP inhibitors were not designed with standardized cardiac end points other than hypertension. For this reason, most reports of cardiotoxicity other than hypertension come from observational studies. Since the approval of these agents, observational studies of sunitinib and sorafenib have demonstrated rates of symptomatic heart failure ranging from 3% to 8% and rates of decreased left ventricular ejection fraction of at least 15%, ranging from 8% to 28%. On discontinuation of the agents, left ventricular function returned to baseline in most, but not all, patients. 18, 19 Less clear is the incidence of cardiomyopathy in the setting of bevacizumab. This may be due to the relatively broad selectivity of receptor tyrosine kinase inhibitors compared with bevacizumab (which exclusively antagonizes VEGF), suggesting a mechanism other than VEGF inhibition leading to cardiomyopathy.
There is growing awareness of the increased risk of venous and arterial thrombotic events in patients treated with VSP inhibitors. A recent metaanalysis of patients on bevacizumab has shown a 12% rate (relative risk, 1.33; PϽ0.01 versus placebo patients) of venous thromboembolism. 20 Similarly, arterial thrombotic events (including strokes and myocardial infarctions) have been shown to be more common in bevacizumab-treated patients, with an incidence of 5.5 events per 100 person-years compared with 3.1 events per 100 person-years among the placebo groups (PϽ0.05). 21 This toxicity was also seen with sunitinib and sorafenib, which carried a relative risk for arterial thrombotic events of 3.03 (PϽ0.05) compared with placebo. 22 In our experience, there is increased incidence of atrial fibrillation in patients treated with VSP inhibitors, although it is unclear whether this is due to hypertension.
These observational studies raise questions for the cardiac management of patients on VSP inhibitors. For example, what is the contribution of hypertension to the various cardiac toxicities? What is the true incidence of cardiac toxicities in the nonclinical trial cancer patient, who may have more cardiac risk factors or previous cardiac history than a patient selected for a cancer clinical trial? Until further studies are done, we recommend a high index of suspicion for underlying cardiac disease, including cardiac ischemia or heart failure, for patients with symptoms on VSP inhibitors and aggressive management of their cardiac risk factors, including hypertension and hyperlipidemia.
Follow-Up of Our Patient
Our patient had already been started on a ␤-blocker (extended-release metoprolol 25 mg once daily) before being sent to our cardio-oncology clinic. However, metoprolol was not sufficient to control his blood pressure as recommended by JNC7 guidelines. In the cardio-oncology clinic, he was noted to be hypertensive, with a blood pressure of 168/98 mm Hg. Lisinopril was added to the extendedrelease metoprolol. Subsequently, amlo-dipine had to be added, resulting in triple antihypertensive medication therapy. The patient has been monitoring his blood pressure at home, where his blood pressure has remained Ͻ140/90 mm Hg. He has remained in normal sinus rhythm with no report of palpitations.
